Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 13/20 | 0.43 |
| ▸ | CTSS | P25774 | 9/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6968497 | 1.00 | CA1 (0.45) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL20803246 | 0.86 | CA1 (0.42) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12635077 | 0.86 | CTSK (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6977978 | 0.86 | CTSK (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12635071 | 0.86 | CTSK (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL24046184 | 0.84 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL26129038 | 0.84 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL26129040 | 0.84 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL3212391 | 0.84 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2405498 | 0.84 | CA1 (0.46) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076620-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076621-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-1157019-B1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | HOFFMANN LA ROCHE (CH) | 2003-03-19 | — | — | EP | disclosed |
| CN-1330647-A | 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 | HOFFMANN LA ROCHE (CH) | 2002-01-09 | — | — | CN | disclosed |
| EP-1157019-A1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| US-6303793-B1 | INTERMEDIATES FOR CYCLIN-DEPENDENT KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6252086-B1 | CYCLIN-DEPENDENT KINASES INHIBITORS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2001-06-26 | — | — | US | disclosed |
| US-6130239-A | INHIBIT CYCLIN-DEPENDENT KINASES | HOFFMANN-LA ROCHE INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000035908-A1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |